Title:
COMPOSITION INCLUDING ESTRAVIRINE TARGETING HOMODIMER OF AGR2 AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER
Document Type and Number:
WIPO Patent Application WO/2023/132577
Kind Code:
A1
Abstract:
The present invention relates to a composition including etravirine (ETR) targeting a homodimer of anterior gradient 2 (AGR2) as an active ingredient for the prevention or treatment of cancer and, more specifically, to a use of etravirine for inhibiting the dimerization of AGR2 and treating colorectal cancer and pancreatic cancer. The compound was found to inhibit the dimerization of AGR2 in a dose-dependent manner and to repress the growth of cancer cells.
Inventors:
YUN JISOO (KR)
KWON SANG-MO (KR)
PARK KICHUL (KR)
CHO ART E (KR)
KWON SANG-MO (KR)
PARK KICHUL (KR)
CHO ART E (KR)
Application Number:
PCT/KR2023/000008
Publication Date:
July 13, 2023
Filing Date:
January 02, 2023
Export Citation:
Assignee:
NAT UNIV PUSAN IND UNIV COOP FOUND (KR)
International Classes:
A61K31/505; A23L33/10; A61P35/00
Foreign References:
| KR20140142594A | 2014-12-12 | |||
| US20170283509A1 | 2017-10-05 | |||
| KR102312100B1 | 2021-10-14 | |||
| KR20210103426A | 2021-08-23 |
Other References:
MARKUS HECHT, SONJA ERBER, THOMAS HARRER, HARTWIG KLINKER, THOMAS ROTH, HANS PARSCH, NORA FIEBIG, RAINER FIETKAU, LUITPOLD V. DIST: "Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells", PLOSONE, vol. 10, no. 6, 18 June 2015 (2015-06-18), pages 1 - 13, XP055713724, DOI: 10.1371/journal.pone.0130277
Attorney, Agent or Firm:
TAEBAEK INTELLECTUAL PROPERTY LAW FIRM (KR)
Download PDF: